Author:
Lee Howard,Kim Kee Sik,Chae Shung Chull,Jeong Myung Ho,Kim Dong-Soo,Oh Byung-Hee
Subject
Pharmacology (medical),Pharmacology
Reference29 articles.
1. Fimasartan;Am J Cardiovasc Drugs,2011
2. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean patients with hypertension: findings from two phase ii, randomized, double-blind, placebo-controlled studies;Lee;Clin Ther,2012
3. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects;Chi;Am J Cardiovasc Drugs,2011
4. Efficacy and Tolerability of Fimasartan, a New Angiotensin Receptor Blocker, Compared With Losartan (50/100 mg): A 12-Week, Phase III, Multicenter, Prospective, Randomized, Double-Blind, Parallel-Group, Dose Escalation Clinical Trial With an Optional 12-Week Extension Phase in Adult Korean Patients With Mild-to-Moderate Hypertension
5. Kanarb (fimasartan potassium) [product information]. Seoul, Korea: Boryung Pharm Co Ltd., September, 2010.
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献